Maryland 2023 Regular Session

Maryland House Bill HB1217

Introduced
2/10/23  
Refer
2/10/23  
Report Pass
3/17/23  
Engrossed
3/20/23  
Refer
3/20/23  
Report Pass
3/30/23  
Enrolled
4/7/23  
Chaptered
5/3/23  

Caption

Maryland Medical Assistance Program and Health Insurance - Required Coverage for Biomarker Testing

Impact

The introduction of HB 1217 is expected to significantly influence state laws regarding health insurance mandates. By standardizing coverage for biomarker testing across various health plans, the bill seeks to enhance patient access to necessary diagnostic tools that can guide treatment decisions for complex medical conditions. It emphasizes the importance of evidence-based medicine, aiming to align medical practices with scientifically validated methods, which stakeholders believe will have a positive impact on overall health outcomes.

Summary

House Bill 1217 mandates that the Maryland Medical Assistance Program, along with certain insurers, nonprofit health service plans, health maintenance organizations, and managed care organizations, provide coverage for biomarker testing. This requirement aims to ensure that tests supported by medical and scientific evidence are accessible to patients, thereby advancing precision medicine and personalized treatment plans. The legislation specifies that coverage will be effective starting January 1, 2024, and outlines particular stipulations regarding deductibles, copayments, and utilization review processes associated with biomarker testing.

Sentiment

Sentiment surrounding HB 1217 is largely supportive among healthcare advocates and patients, who view it as a crucial step towards improving access to innovative medical testing that can lead to better health outcomes. Proponents emphasize the importance of biomarker testing in modern healthcare, arguing that understanding individual patient needs through advanced diagnostics can lead to more effective and personalized treatment strategies. However, some concerns may be raised about the logistical implications for healthcare providers and insurance companies regarding the implementation of these new coverage mandates.

Contention

Notable points of contention surrounding HB 1217 include concerns about the potential cost implications for insurers and the Maryland Medical Assistance Program. Stakeholders have debated the feasibility of ensuring timely approvals for testing to prevent delays in patient care. Additionally, there may be discussions regarding the criteria for what constitutes acceptable evidence to support the necessity and efficacy of specific biomarker tests, which could affect how broadly the law is interpreted and applied in practice.

Companion Bills

MD SB805

Crossfiled Maryland Medical Assistance Program and Health Insurance – Required Coverage for Biomarker Testing

Previously Filed As

MD SB805

Maryland Medical Assistance Program and Health Insurance – Required Coverage for Biomarker Testing

MD SB60

Maryland Medical Assistance Program and Health Insurance - Required Coverage for Calcium Score Testing

MD HB666

Maryland Medical Assistance Program and Health Insurance - Required Coverage for Calcium Score Testing

MD HB1137

Maryland Medical Assistance Program and Health Insurance - Required Coverage for Calcium Score Testing

MD SB961

Maryland Medical Assistance Program and Health Insurance - Pharmacogenomic Testing - Required Coverage

MD HB665

Maryland Medical Assistance Program and Health Insurance - Annual Behavioral Health Wellness Visits - Coverage and Reimbursement

MD SB328

Maryland Medical Assistance Program and Health Insurance - Annual Behavioral Health Wellness Visits - Coverage and Reimbursement

MD HB1376

Maryland Medical Assistance Program, Maryland Children's Health Program, and Health Insurance - Special Pediatric Hospitals

MD HB400

Maryland Medical Assistance Program and Health Insurance - Annual Behavioral Health Wellness Visits - Coverage and Reimbursement

MD HB1301

Maryland Medical Assistance Program, Maryland Children’s Health Program, and Health Insurance – Transfers to Special Pediatric Hospitals – Prior Authorizations

Similar Bills

MD HB950

Maryland Native Plants Program

MD SB836

Maryland Native Plants Program

MD HB161

Northeast Maryland Waste Disposal Authority - Evaluation, Termination of Bond Authority, and Assumption of Functions, Employees, and Contracts (Northeast Maryland Waste Disposal Authority Sunset Act)

MD HB1124

Maryland Department of Health - 2-1-1 Maryland, Maryland Think, and Maryland OneStop - Study

DE HCR156

Urging The State Of Maryland To Allow The Sale Of Certified Delaware Sod In Maryland.

MD SB14

Sustainable Maryland Program and Fund - Establishment

MD HB530

Maryland Trails Advisory Committee and the Maryland Office of Trails - Establishment (Great Maryland Trails Act)

MD SB645

Maryland Trails Advisory Committee and the Maryland Office of Trails - Establishment (Great Maryland Trails Act)